SCHEMBL83159

SCHEMBL83159

COc1ccccc1C[O]

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.57
TAAR1 Q96RJ0 1/20 0.57
CHRM2 P08172 3/20 0.55
CHRM1 P11229 2/20 0.55
CA1 P00915 3/20 0.55
CA2 P00918 3/20 0.55
CA9 Q16790 3/20 0.55
CA7 P43166 2/20 0.55
CA12 O43570 2/20 0.55
CA14 Q9ULX7 2/20 0.55
CA4 P22748 1/20 0.55
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
HTT P42858 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SIGMAR1 Q99720 1/20 0.50
AOC3 Q16853 1/20 0.50
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17939 0.83 IDO1 (0.59) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL1805222 0.82 TAAR1 (0.64) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL4615134 0.81 IDO1 (0.57) IDO1TAAR1CHRM2CHRM1CA1
Ammonia Solution, Strong SCHEMBL265951 0.81 IDO1 (0.57) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL95872 0.80 CA12 (0.53) CA1CA2CA12CA14ALDH1A1
SCHEMBL27487579 0.80 IDO1 (0.42) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL28858018 0.80 TAAR1 (0.75) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL3296809 0.80 IDO1 (0.61) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL422832 0.79 HTR2A (0.44) IDO1TAAR1CHRM2CHRM1CA1
SCHEMBL7672632 0.79 IDO1 (0.41) IDO1TAAR1CHRM2CHRM1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024111390-A1 COMPOUND AND METHOD FOR PRODUCING SAME 学校法人帝京大学 2024-05-30 WO claimed
WO-2020191503-A1 METHODS AND USES OF BROMANTANE AND DERIVATIVES THEREOF FOR TREATING LUNG DISEASE, FATTY LIVER DISEASE, AND KIDNEY DISORDERS ALGERNON PHARMACEUTICALS INC. (CA) 2020-10-01 WO claimed
CN-109096337-B A kind of phospha indole derivatives, benzo phospha indole derivatives and preparation method thereof 苏州大学 2019-11-22 CN claimed
EP-3160977-A2 BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS The University of Kansas (US) 2017-05-03 EP claimed
WO-2015200514-A2 BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS THE UNIVERSITY OF KANSAS (US) 2015-12-30 WO claimed
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-07-09 US claimed
WO-2013086131-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-06-13 WO claimed
US-8129386-B2 Fused azole-pyrimidine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-06 US claimed
US-8071651-B2 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension NOVARTIS AG (CH) 2011-12-06 US claimed
US-7868036-B2 Organic compounds NOVARTIS AG (CH) 2011-01-11 US claimed
US-4734495-A Process and intermediates for beta-lactam antibiotics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1988-03-29 US claimed
US-4675400-A FORM CONJUGATES WITH IMMUNOGLOBULINS; ANTITUMOR AGENTS ELI LILLY AND COMPANY (US) 1987-06-23 US claimed
US-4596676-A Bifunctional ester derivatives of 4-desacetyl indole-dihydroindole alkaloids LILLY INDUSTRIES LIMITED (GB) 1986-06-24 US claimed
EP-0123441-A1 Vincaleukoblastine derivatives LILLY INDUSTRIES LIMITED (GB) 1984-10-31 EP claimed
US-4331597-A AMOXYCILLIN DERIVATIVES MEIJI SEIKA KAISHA, LTD. (JP) 1982-05-25 US claimed
US-4269990-A CHEMICAL INTERMEDIATES FOR 1-UNSUBSTITUTED-2-(4-INDANYL- OR 5-NAPHTHYLAMINO)-2-IMIDAZOLINE, USEFUL AS DRUGS BASF AKTIENGESELLSCHAFT (DE) 1981-05-26 US claimed
US-4232151-A ANTIBIOTICS SHIONOGI & CO., LTD. (JP) 1980-11-04 US claimed
US-4079181-A INTERMEDIATES FOR 3-HYDROXY-3-CEPHEM COMPOUNDS SHIONOGI & CO., LTD. (JA) 1978-03-14 US claimed
US-4073902-A ANTIMICROBIAL COMPOUNDS CIBA-GEIGY CORPORATION (US) 1978-02-14 US claimed
US-4009277-A 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents AMERICAN CYANAMID COMPANY (US) 1977-02-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A HAVCR2, HDLBP, HSP90B1 IDO1 342/4885TAAR1 3193/4885CHRM2 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.